177 related articles for article (PubMed ID: 9816049)
1. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration.
Sosman JA; Bartemes K; Offord KP; Kita H; Fisher SG; Kefer C; Ellis TA; Fisher RI; Higgins TJ; Gleich GJ
Clin Cancer Res; 1995 Aug; 1(8):805-12. PubMed ID: 9816049
[TBL] [Abstract][Full Text] [Related]
2. Eosinophil-fibroblast interactions. Granule major basic protein interacts with IL-1 and transforming growth factor-beta in the stimulation of lung fibroblast IL-6-type cytokine production.
Rochester CL; Ackerman SJ; Zheng T; Elias JA
J Immunol; 1996 Jun; 156(11):4449-56. PubMed ID: 8666820
[TBL] [Abstract][Full Text] [Related]
3. Eosinophil degranulation. An immunologic determinant in the pathogenesis of the Mazzotti reaction in human onchocerciasis.
Ackerman SJ; Kephart GM; Francis H; Awadzi K; Gleich GJ; Ottesen EA
J Immunol; 1990 May; 144(10):3961-9. PubMed ID: 2332637
[TBL] [Abstract][Full Text] [Related]
4. The influence of IL-3, IL-5, and GM-CSF on normal human eosinophil and neutrophil C3b-induced degranulation.
Carlson M; Peterson C; Venge P
Allergy; 1993 Aug; 48(6):437-42. PubMed ID: 8238799
[TBL] [Abstract][Full Text] [Related]
5. Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils.
Kita H; Abu-Ghazaleh RI; Sur S; Gleich GJ
J Immunol; 1995 May; 154(9):4749-58. PubMed ID: 7722326
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis.
Yamazaki K; Suzuki K; Nakamura A; Sato S; Lindor KD; Batts KP; Tarara JE; Kephart GM; Kita H; Gleich GJ
Hepatology; 1999 Jul; 30(1):71-8. PubMed ID: 10385641
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome.
Simon HU; Plötz S; Simon D; Seitzer U; Braathen LR; Menz G; Straumann A; Dummer R; Levi-Schaffer F
Eur J Immunol; 2003 Apr; 33(4):834-9. PubMed ID: 12672048
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of neutrophil interleukin-8 production by eosinophil granule major basic protein.
Page SM; Gleich GJ; Roebuck KA; Thomas LL
Am J Respir Cell Mol Biol; 1999 Aug; 21(2):230-7. PubMed ID: 10423406
[TBL] [Abstract][Full Text] [Related]
10. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
Hank JA; Albertini M; Wesly OH; Schiller JH; Borchert A; Moore K; Bechhofer R; Storer B; Gan J; Gambacorti C
Clin Cancer Res; 1995 May; 1(5):481-91. PubMed ID: 9816007
[TBL] [Abstract][Full Text] [Related]
11. Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells.
Silberstein DS; Schoof DD; Rodrick ML; Tai PC; Spry CJ; David JR; Eberlein TJ
J Immunol; 1989 Mar; 142(6):2162-7. PubMed ID: 2784151
[TBL] [Abstract][Full Text] [Related]
12. Conjunctival fibroblasts enhance the survival and functional activity of peripheral blood eosinophils in vitro.
Solomon A; Shmilowich R; Shasha D; Frucht-Pery J; Pe'er J; Bonini S; Levi-Schaffer F
Invest Ophthalmol Vis Sci; 2000 Apr; 41(5):1038-44. PubMed ID: 10752939
[TBL] [Abstract][Full Text] [Related]
13. Interferon-gamma enhances human eosinophil effector functions induced by granulocyte-macrophage colony-stimulating factor or interleukin-5.
Yamaguchi T; Kimura H; Kurabayashi M; Kozawa K; Kato M
Immunol Lett; 2008 Jun; 118(1):88-95. PubMed ID: 18440651
[TBL] [Abstract][Full Text] [Related]
14. Effect of inhaled interleukin-5 on number and activity of eosinophils in circulation from asthmatics.
Shi HZ; Li CQ; Qin SM; Xie ZF; Liu Y
Clin Immunol; 1999 May; 91(2):163-9. PubMed ID: 10227808
[TBL] [Abstract][Full Text] [Related]
15. Interaction of IL 1 and TPA in modulation of eosinophil function.
Pincus SH; Whitcomb EA; Dinarello CA
J Immunol; 1986 Dec; 137(11):3509-14. PubMed ID: 3023484
[TBL] [Abstract][Full Text] [Related]
16. Increased eosinophil infiltration and degranulation in colonic tissue from patients with collagenous colitis.
Levy AM; Yamazaki K; Van Keulen VP; Burgart LJ; Sandborn WJ; Phillips SF; Kephart GM; Gleich GJ; Leiferman KM
Am J Gastroenterol; 2001 May; 96(5):1522-8. PubMed ID: 11374693
[TBL] [Abstract][Full Text] [Related]
17. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients.
Sosman JA; Fisher SG; Kefer C; Fisher RI; Ellis TM
Ann Oncol; 1994 May; 5(5):447-52. PubMed ID: 7521206
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
Bukowski RM; Olencki T; Gunn H; McLain D; Budd GT; Sandstrom K; Tuason L; Redovan C; Rayman P; Tubbs R; Resta D; Elson P; Finke J
Clin Cancer Res; 1996 Feb; 2(2):347-57. PubMed ID: 9816178
[TBL] [Abstract][Full Text] [Related]
20. Eosinophil major basic protein: first identified natural heparanase-inhibiting protein.
Temkin V; Aingorn H; Puxeddu I; Goldshmidt O; Zcharia E; Gleich GJ; Vlodavsky I; Levi-Schaffer F
J Allergy Clin Immunol; 2004 Apr; 113(4):703-9. PubMed ID: 15100677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
